Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rurioctocog alfa pegol - Takeda

Drug Profile

Rurioctocog alfa pegol - Takeda

Alternative Names: Adynovate; Adynovi; BAX-855; EHL rFVIII PEG; Extended half-life recombinant FVIII; Full-length longer-acting rFVIII; LA rFVIII PEG; PEG factor VIII; PEGylated recombinant factor VIII; PEGylated rFVIII; SHP-660; TAK 660

Latest Information Update: 14 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International; Nektar Therapeutics
  • Developer Baxter International; Nektar Therapeutics; Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 27 Mar 2023 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, Prevention, Treatment-experienced) in China (IV) (NCT05707351)
  • 27 Mar 2023 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, Treatment-experienced) in China (IV) (NCT05707351)
  • 07 Feb 2023 Takeda plans a phase III trial for Haemophilia A (In children, In adolescents, In adults, Treatment-experienced, Prevention) in China (IV) (NCT05707351)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top